Your region is set to . If this is incorrect, please change your region.

Life Sciences

Our life sciences experts work with a global client base, helping them to protect and realise value from their products and devices.

Clients include some of the world's leading pharmaceutical giants such as AstraZeneca and GlaxoSmithKline, and the latest biotech start-ups such as arGEN-X and Heptares Therapeutics.

They all have sector-specific requirements and need lawyers who can help navigate the heavily regulated landscape. Lawyers with the sector expertise to respond to IP threats quickly and effectively. And lawyers who understand the challenge of recouping investment given the increasing costs to develop drugs and difficulty of getting new products to market.

Fully immersed in the sector, many of us have life sciences degrees and have spent time in our careers as scientists. This means we have the hands-on experience to understand your operating environment, commercial needs and challenges.

'Blockbuster' pharmaceutical products are the life-blood of many pharmaceutical companies. Defending legitimate monopolies protecting such products requires an intimate knowledge of both the procedural aspects and substantive case-law of the Patent Courts - not just in the UK, but across the EU and globally.

Our IP litigators have decades of experience of highly technical patent disputes in the life sciences sector and an impressive record of achieving success for their clients. Whether 'small molecules', 'biosimilars', 'medical devices' or a whole range of other patents types, our team has both the technical and legal background and experience to provide advice of the highest quality.

The desire of the big pharmaceutical companies to fill their pipelines of new drugs, coupled with increasing amounts of money available for early-stage companies, is fuelling a lively transactions market. Trusted advisers to clients across the globe on collaborations and M&A transactions, we lead on the sector's most widely-reported deals.

Speaking at world-leading events such as the BIO Advanced Business Development course at BIO-Europe and BIO in the US, team members are also actively involved in bodies such as the Association of the British Pharmaceutical Industry and the Bioindustry Association. Through this involvement with leading sector bodies, as well as regular contributions to the key professional publications, the team are thought leaders on the latest issues.

We are ranked as a leading firm for life sciences in Chambers UK and as a leading firm for pharmaceuticals and biotechnology in The Legal 500 UK.

"One of the country's leading transactional life sciences practices, which focuses on the full range of commercial agreements particular to the sector. The firm also has a formidable offering in patent litigation. A very strong team indeed." - Chambers UK 2015

Lawyer quotes from Chambers UK 2015:

Patrick Duxbury is one of the most respected transactional lawyers in the life sciences sector. He "combines a very sophisticated approach to contract construction and negotiation with sage advice that we have come to appreciate and trust greatly," said one interviewee. Patrick is ranked as the only 'star individual' for life sciences: transactional, UK-wide.

Paul Inman is described by sources as a "very accomplished" contentious lawyer, who specialises in high-stakes pharmaceuticals patent litigation. He led the team defending Lundbeck against Resolution Chemicals' challenge to its blockbuster escitalopram.

Luke Kempton advises market leaders and emerging companies on all manner of collaboration and licence agreements. He is commended for his "great commitment to and focus on the sector".

Key Contact

Meet our Life Sciences professionals

View all

Life Sciences Client Work

Related Insights & Resources

UK Supreme Court introduces doctrine of equivalents in patent law in Actavis v Lilly

Ailsa Carter, Gordon Harris

Articles 13 July 2017

The fight against counterfeit pharmaceutical products intensifies

Vanessa Delnaud

Articles 15 May 2017

Ground-breaking declaratory relief from English High Court clears the route to market for Humira biosimilar

Paul Inman, Jenny Davies

Articles 06 March 2017

What Brexit means for life sciences

Articles 11 January 2017

UK signals intent to remain in the new Unified Patent Court system

Gordon Harris, Nick Cunningham

Articles 30 November 2016

Eli Lilly's erectile dysfunction patent stands up to scrutiny

Christopher Freeth, Paul Inman

Articles 01 September 2016

English Patents Court rules patent not infringed four months after claim filed

Ailsa Carter, Paul Inman

Articles 14 July 2016

Brexit - what vote Leave means for UK life sciences

Patrick Duxbury, John P Cooper

Articles 04 July 2016

Subscribe to our updates